Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Inclusion Criteria: 1. Age 18-75 years old (including 18, 75 years old), gender is not limited; 2. According to WHO (2020) criteria, the subjects are diagnosed for recurrent or refractory t(8:21) acute myeloid leukemia or demonstrated persistant AML1-ETO positiving or genetic MRD recurrence after ≥3 cycles of intensive chemotherapy, as confirmed by quantitative PCR; 3. The subjects voluntarily participate in the study and sign the Informed Consent Form by themselves or their legal guardians; 4. The HLA types of subjects are HLA-A\* 11:01 or HLA-A\*02:01; 5. Possessing the AML1-ETO(RUNX1-RUNX1T1) funsion gene; 6. Disease progression after adequate first-line systemic treatment for remission, or disease progression after first-line or above systemic systemic treatment for ≥2 cycles , or without remission (CR or PR) after≥4 cycles of treatment ; 7. No contraindications for collection of mononuclear cells from peripheral blood ; 8. ECOG score ≤1; 9. The survival time is exspected to be≥ 3 months; 10. Have the ability to understand and be willing to sign the informed consent for this test. Exclusion Criteria: 1. Tumor cells do not express AML1-ETO neoantigen; 2. Active infection; 3. Abnormal liver function \[TBil（total bilirubin)\>1.5×ULN, ALT\>2.5×ULN\], abnormal kidney function \[Scr（serum creatinine)\>1.5×ULN\]; 4. Unstable angina or 3/4 class of congestive heart failure according to New York Heart Association, or multiple organ dysfunction; 5. HIV/AIDS patients; 6. Participants who need treatment of long-term anticoagulation (warfarin or heparin) or antiplatelet(aspirin\>300mg/d; Clopidogrel\>75mg/d) ; 7. Participants who received radiotherapy within 4 weeks ,prior to study initiation (blood collection); 8. Known or suspected drug abuse or alcohol dependence; 9. Patients with mental disorders or other medical conditions are unable to obtain informed consent and cooperate to complete the requirements of experimental treatment and examination procedures; 10. Participants in other clinical trials within 30 days; 11. Pregnant or lactating women and male subjects (or their partners) or female subjects who plan to become pregnant during the study period and within 6 months after the end of the study ,and do not wish to use a medically approved effective contraceptive method (such as an IUD or condom) during the study period; 12. The investigator evaluates that the subject is unable or unwilling to comply with the requirements of the study protocol;